Good clinical response to alectinib, a second generation ALK inhibitor, in refractory neuroblastoma

Saved in:
Bibliographic Details
Published inPediatric blood & cancer Vol. 65; no. 7; pp. e27055 - n/a
Main Authors Heath, John A., Campbell, Marty A., Thomas, Alison, Solomon, Ben
Format Journal Article
LanguageEnglish
Published United States Wiley Subscription Services, Inc 01.07.2018
Subjects
Hematology
Neuroblastoma
Oncology
Pediatrics
Online AccessGet full text

Cover

Author Campbell, Marty A.
Heath, John A.
Solomon, Ben
Thomas, Alison
Author_xml – sequence: 1
  givenname: John A.
  orcidid: 0000-0002-6243-0669
  surname: Heath
  fullname: Heath, John A.
  email: john.heath@ths.tas.gov.au
  organization: Royal Hobart Hospital
– sequence: 2
  givenname: Marty A.
  surname: Campbell
  fullname: Campbell, Marty A.
  organization: Royal Children's Hospital
– sequence: 3
  givenname: Alison
  surname: Thomas
  fullname: Thomas, Alison
  organization: Royal Hobart Hospital
– sequence: 4
  givenname: Ben
  surname: Solomon
  fullname: Solomon, Ben
  organization: Peter MacCallum Cancer Institute
BackLink https://www.ncbi.nlm.nih.gov/pubmed/29603581$$D View this record in MEDLINE/PubMed
BookMark eNp1kMtOwzAQRS1URB-w4AeQJVZIfdhO7CTLUkFBVIIFrC3bccBVagc7EerfY0jpjtU8dObOzB2DgXVWA3CJ0RwjRBaNVHOSIUpPwAjTlM4owtngmKNiCMYhbCPKEM3PwJAUDCU0xyOg1s6VUNXGGiVq6HVonA0atg6KWqs29uUUChi0craE79pqL1rjLFxunqCxH0aa1vlpTONw5YWK1R5a3XknaxFatxPn4LQSddAXhzgBb_d3r6uH2eZ5_bhabmYqoZTOyvhCxqqyKChiIpE6xRUrcipVUhKCMSqQTMqcKIW0yJjCjOhCCIYiq2I7mYDrXrfx7rPToeVb13kbV3KC0ixNWJrnkbrpKeVdCPFm3nizE37PMeI_dvJoJ_-1M7JXB8VO7nR5JP_8i8CiB75Mrff_K_GX21Uv-Q0bDoBI
CitedBy_id crossref_primary_10_3390_cancers13143531
crossref_primary_10_3390_cancers15030560
crossref_primary_10_1111_apm_12940
crossref_primary_10_3390_cancers15194722
crossref_primary_10_1007_s40278_019_62571_6
crossref_primary_10_1038_s41698_023_00449_x
crossref_primary_10_1089_thy_2019_0041
crossref_primary_10_1080_08880018_2021_1907493
crossref_primary_10_1038_s41598_019_55060_7
crossref_primary_10_1097_MPH_0000000000001485
crossref_primary_10_1016_j_bcp_2023_115751
crossref_primary_10_1101_mcs_a006064
crossref_primary_10_1158_1078_0432_CCR_21_3521
crossref_primary_10_3390_pharmaceutics13091427
crossref_primary_10_1080_08880018_2018_1541492
crossref_primary_10_1177_1078155219852670
crossref_primary_10_3390_cancers15174252
crossref_primary_10_1007_s11912_022_01270_8
crossref_primary_10_3390_ijms222312883
crossref_primary_10_3389_fonc_2019_00579
Cites_doi 10.1016/j.lungcan.2015.11.023
10.1016/S1470-2045(13)70095-0
10.1038/nrclinonc.2012.72
10.1056/NEJMoa1704795
10.1016/S1470-2045(14)70362-6
10.1158/1078-0432.CCR-14-1511
10.3892/ijo.2017.4140
ContentType Journal Article
Copyright 2018 Wiley Periodicals, Inc.
Copyright_xml – notice: 2018 Wiley Periodicals, Inc.
DBID NPM
AAYXX
CITATION
7T5
7TK
7TO
8FD
FR3
H94
K9.
P64
RC3
DOI 10.1002/pbc.27055
DatabaseName PubMed
CrossRef
Immunology Abstracts
Neurosciences Abstracts
Oncogenes and Growth Factors Abstracts
Technology Research Database
Engineering Research Database
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Biotechnology and BioEngineering Abstracts
Genetics Abstracts
DatabaseTitle PubMed
CrossRef
Genetics Abstracts
Oncogenes and Growth Factors Abstracts
Technology Research Database
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Immunology Abstracts
Engineering Research Database
Neurosciences Abstracts
Biotechnology and BioEngineering Abstracts
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1545-5017
EndPage n/a
ExternalDocumentID 10_1002_pbc_27055
29603581
PBC27055
Genre letter
Letter
Correspondence
Letter to the Editor
GroupedDBID ---
.3N
.GA
.Y3
05W
0R~
10A
123
1L6
1OC
31~
33P
3SF
3WU
4.4
4ZD
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5VS
66C
6PF
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A01
A03
AAESR
AAEVG
AAHHS
AANLZ
AAONW
AASGY
AAWTL
AAXRX
AAZKR
ABCQN
ABCUV
ABEML
ABIJN
ABPPZ
ABPVW
ABQWH
ABXGK
ACAHQ
ACBWZ
ACCFJ
ACCZN
ACFBH
ACGFS
ACGOF
ACIWK
ACMXC
ACPOU
ACPRK
ACSCC
ACXBN
ACXQS
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADOZA
ADXAS
ADZMN
AEEZP
AEIGN
AEIMD
AENEX
AEQDE
AEUQT
AEUYR
AFBPY
AFFPM
AFGKR
AFPWT
AFRAH
AFZJQ
AHBTC
AHMBA
AIACR
AITYG
AIURR
AIWBW
AJBDE
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
AMBMR
AMYDB
ATUGU
AZBYB
AZFZN
AZVAB
BAFTC
BDRZF
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BY8
C45
CS3
D-6
D-7
D-E
D-F
DCZOG
DPXWK
DR2
DRFUL
DRMAN
DRSTM
DU5
EBD
EBS
EJD
EMOBN
F00
F01
F04
F5P
FEDTE
FUBAC
G-S
G.N
GNP
GODZA
H.X
HBH
HF~
HGLYW
HHY
HHZ
HVGLF
HZ~
IX1
J0M
JPC
KBYEO
KQQ
LATKE
LAW
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
MEWTI
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N9A
NF~
NNB
O66
O9-
OIG
OVD
P2W
P2X
P2Z
P4B
P4D
PQQKQ
Q.N
Q11
QB0
QRW
R.K
ROL
RWI
RX1
RYL
SUPJJ
SV3
TEORI
UB1
UDS
V2E
W8V
W99
WBKPD
WHWMO
WIH
WIJ
WIK
WJL
WOHZO
WQJ
WRC
WVDHM
WXI
WXSBR
XG1
XV2
~IA
~WT
NPM
AAYXX
CITATION
7T5
7TK
7TO
8FD
FR3
H94
K9.
P64
RC3
ID FETCH-LOGICAL-c3555-d27076fd99506a3be41f6985bc3d2211090b3d82cc0ea76c162e9aa60a3bc82c3
IEDL.DBID DR2
ISSN 1545-5009
IngestDate Thu Oct 10 17:34:56 EDT 2024
Fri Aug 23 03:29:07 EDT 2024
Wed Oct 16 00:51:34 EDT 2024
Sat Aug 24 01:05:19 EDT 2024
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 7
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c3555-d27076fd99506a3be41f6985bc3d2211090b3d82cc0ea76c162e9aa60a3bc82c3
ORCID 0000-0002-6243-0669
OpenAccessLink http://minerva-access.unimelb.edu.au/bitstreams/372212b4-de17-5dd8-9cee-f9e701053ed0/download
PMID 29603581
PQID 2047436488
PQPubID 1036357
PageCount 2
ParticipantIDs proquest_journals_2047436488
crossref_primary_10_1002_pbc_27055
pubmed_primary_29603581
wiley_primary_10_1002_pbc_27055_PBC27055
PublicationCentury 2000
PublicationDate July 2018
2018-07-00
20180701
PublicationDateYYYYMMDD 2018-07-01
PublicationDate_xml – month: 07
  year: 2018
  text: July 2018
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: Glenview
PublicationTitle Pediatric blood & cancer
PublicationTitleAlternate Pediatr Blood Cancer
PublicationYear 2018
Publisher Wiley Subscription Services, Inc
Publisher_xml – name: Wiley Subscription Services, Inc
References 2017; 51
2014; 15
2013; 14
2016; 92
2017; 377
2012; 9
2014; 20
e_1_2_3_2_1
e_1_2_3_6_1
e_1_2_3_5_1
e_1_2_3_4_1
e_1_2_3_3_1
e_1_2_3_8_1
e_1_2_3_7_1
References_xml – volume: 9
  start-page: 391
  year: 2012
  article-title: Targeting ALK in neuroblastoma—preclinical and clinical advancements
  publication-title: Nat Rev Clin Oncol
– volume: 14
  start-page: 472
  year: 2013
  end-page: 480
  article-title: Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large‐cell lymphoma: a Children's Oncology Group phase 1 consortium study
  publication-title: Lancet Oncol
– volume: 15
  start-page: 1119
  year: 2014
  end-page: 1128
  article-title: Safety and efficacy of alectinib against systemic disease and brain metastases in patients with crizotinib‐resistant ALK‐rearranged non‐small‐cell lung cancer (AF‐002JG): results from the dose‐finding portion of a phase ½ study
  publication-title: Lancet Oncol
– volume: 51
  start-page: 1533
  year: 2017
  end-page: 1540
  article-title: Activation of Src signalling mediates acquired resistance to ALK inhibition in lung cancer
  publication-title: Int J Oncol
– volume: 20
  start-page: 5686
  year: 2014
  end-page: 5696
  article-title: Two novel ALK mutations mediate acquired resistance to the next‐generation ALK inhibitor alectinib
  publication-title: Clin Cancer Res
– volume: 377
  start-page: 829
  year: 2017
  end-page: 838
  article-title: Alectinib versus crizotinib in untreated ALK‐positive non‐small‐cell lung cancer
  publication-title: N Engl J Med
– volume: 92
  start-page: 19
  year: 2016
  end-page: 21
  article-title: A novel acquired ALK F1245C mutation confers resistance to crizotinib in ALK‐positive NSLC but is sensitive to ceritinib
  publication-title: Lung Cancer
– ident: e_1_2_3_5_1
  doi: 10.1016/j.lungcan.2015.11.023
– ident: e_1_2_3_3_1
  doi: 10.1016/S1470-2045(13)70095-0
– ident: e_1_2_3_2_1
  doi: 10.1038/nrclinonc.2012.72
– ident: e_1_2_3_4_1
  doi: 10.1056/NEJMoa1704795
– ident: e_1_2_3_6_1
  doi: 10.1016/S1470-2045(14)70362-6
– ident: e_1_2_3_7_1
  doi: 10.1158/1078-0432.CCR-14-1511
– ident: e_1_2_3_8_1
  doi: 10.3892/ijo.2017.4140
SSID ssj0026058
Score 2.3683777
SourceID proquest
crossref
pubmed
wiley
SourceType Aggregation Database
Index Database
Publisher
StartPage e27055
SubjectTerms Hematology
Neuroblastoma
Oncology
Pediatrics
Title Good clinical response to alectinib, a second generation ALK inhibitor, in refractory neuroblastoma
URI https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fpbc.27055
https://www.ncbi.nlm.nih.gov/pubmed/29603581
https://www.proquest.com/docview/2047436488
Volume 65
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LSwMxEB6KB_Hi-1GtEsSDB7duk-wLT7U-iloRseBBWPKqFrEr7XrQX-8k261UEcRbCEnIZjKTb7IzXwD2AiGpimKJvomKPa452sGEo14JzaKI9QyPbYJz5zpsd_nFfXBfgaMyF6bgh5hcuFnNcPbaKriQo8Mv0tBXqerUcsGg_W2wyIZzndxOqKMsTHdpcIgQvACBRMkq5NPDSc_ps-gHwJzGq-7AOVuAh3KqRZzJc_0tl3X18Y3F8Z_fsgjzYyBKmsXOWYKKGSzDbGf8q30F1HmWaVImTpJhEUtrSJ4RYa_6sV4eEEFG1qPW5NHRV1spk-bVJekPnvoSjcXwAIvYuTd07_q8E8efKRGy59mLWIXu2eldq-2NX2TwFOKSwNM4ySjs6SQJ_FAwaXijFyZxIBXT1LqSiS-ZjqlSvhFRqBohNYkQoY9tFVazNZgZZAOzAUSiH0MToxjXhmsUlrZkgFEj0FowJf0q7JaySV8L4o20oFimKS5X6parCrVSaulY90Yp9TnCohAtUxXWC0lORqDosFnGtyrsO3n8PnR6c9xyhc2_N92COcRTcRHNW4OZfPhmthGz5HLHbc5PcxfmFg
link.rule.ids 315,783,787,1378,27938,27939,46308,46732
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LSwMxEB60gnrx_ajPIB48uHWbZF_gxXfVVkQUvMiSV1XEbqnrQX-9k2y3oiKItxCSkM1kJt_MZr4AbAZCUhXFEn0TFXtcc7SDCUe9EppFEWsbHtsE59ZF2LjhZ7fB7RDslrkwBT_EIOBmNcPZa6vgNiC988ka2pWqRi0ZzDCMoLoz-37B4dWAPMoCdZcIhxjBCxBKlLxCPt0ZdP16Gv2AmF8RqztyjifhrpxscdPkqfaay5p6_8bj-N-vmYKJPhYle8XmmYYh05mB0Vb_b_ssqJMs06TMnSS94jqtIXlGhI32Y73cJoK8WKdak3vHYG0FTfaa5-Sx8_Ao0V70trGInds997TPG3EUmhJRe549izm4OT66Pmh4_UcZPIXQJPA0TjIK2zpJAj8UTBpeb4dJHEjFNLXeZOJLpmOqlG9EFKp6SE0iROhjW4XVbB4qnaxjFoFIdGVoYhTj2nCN0tKWDzCqB1oLpqRfhY1SOGm34N5IC5ZlmuJypW65qrBSii3tq99LSn2OyChE41SFhUKUgxEo-myW9K0KW04gvw-dXu4fuMLS35uuw1jjutVMm6cX58swjvAqLi73rkAl772aVYQwuVxzO_UD1o_qMA
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9wwEB7ygJBL2vSRbJuHCDn0sN71SrJs01Ne27xZShf2UDB6OVlK14vjHJpfn5G83pCUQslNCEnIGs3oG3nmE8B-JBXVcaLQN9FJwA1HO5hy1CtpWByz3PLEJThfXYvTIT8fRaMF-NrkwtT8EPMLN6cZ3l47BZ-avPtEGjpVukMdF8wiLHPBQhfPdfx9zh3lcLrPg0OIEESIJBpaoZB2512fH0Z_IczngNWfOP038LOZax1o8qtzX6mOfnhB4_jKj3kLazMkSg7qrbMOC3byDlauZv_a34P-VhSGNJmTpKyDaS2pCiLdXT_WqzaR5M651IbceP5qJ2ZycHlBxpPbsUJrUbaxiJ3z0j_s84d4Ak2FmL0qfssPMOyf_Dg6DWZPMgQagUkUGJxkLHKTplEoJFOW93KRJpHSzFDnS6ahYiahWodWxkL3BLWplCLEthqr2UdYmhQTuwlEoSNDU6sZN5YbFJZxbIBxLzJGMq3CFuw1ssmmNfNGVnMs0wyXK_PL1YKtRmrZTPnuMhpyxEUCTVMLNmpJzkeg6LE5yrcWfPHy-PfQ2eDwyBc-_X_TXVgZHPezy7Pri8-witgqqSN7t2CpKu_tNuKXSu34ffoILPfo3w
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Good+clinical+response+to+alectinib%2C+a+second+generation+ALK+inhibitor%2C+in+refractory+neuroblastoma&rft.jtitle=Pediatric+blood+%26+cancer&rft.au=Heath%2C+John+A.&rft.au=Campbell%2C+Marty+A.&rft.au=Thomas%2C+Alison&rft.au=Solomon%2C+Ben&rft.date=2018-07-01&rft.issn=1545-5009&rft.eissn=1545-5017&rft.volume=65&rft.issue=7&rft.epage=n%2Fa&rft_id=info:doi/10.1002%2Fpbc.27055&rft.externalDBID=10.1002%252Fpbc.27055&rft.externalDocID=PBC27055
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1545-5009&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1545-5009&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1545-5009&client=summon